Ge Long Hui·2025-05-20 00:06Core Insights - The collaboration between 3SBio and Pfizer marks a significant milestone in the internationalization journey of 3SBio, highlighting the global recognition of SSGJ-707's clinical efficacy and the company's competitive edge in innovation [2][3] Group 1: Agreement Details - 3SBio and its subsidiaries have granted Pfizer exclusive rights to develop, manufacture, and commercialize the innovative PD-1/VEGF bispecific antibody SSGJ-707 globally, excluding mainland China [1] - 3SBio will retain rights for SSGJ-707 in mainland China and grant Pfizer an option for commercialization in that region based on agreed financial terms [1] - The agreement includes a non-refundable upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, along with a double-digit percentage sales royalty based on product sales in the licensed territories [1] Group 2: Product Information - SSGJ-707 is developed based on the CLF2 patent platform and targets both PD-1 and VEGF, showing promising objective response rates (ORR) and disease control rates (DCR) in non-small cell lung cancer (NSCLC) patients [2] - The drug has received breakthrough therapy designation from the National Medical Products Administration for first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC and has also obtained IND approval from the FDA [2] - Clinical research for SSGJ-707 is ongoing in other areas, including colorectal cancer and gynecological tumors [2] Group 3: Strategic Implications - This partnership is expected to accelerate the global development and commercialization of SSGJ-707, enhancing 3SBio's global strategy and financial returns [2][3] - The collaboration is anticipated to strengthen 3SBio's position in the oncology treatment field and integrate the company further into the global biopharmaceutical value chain [2][3]